ViaCyte
Latest round
- Series D
Last raised
- Jun 2021
Total raised
- $134M
Investors
- 17
About ViaCyte
ViaCyte, Inc.Founded in 1999 and headquartered in San Diego, US, ViaCyte, Inc. specializes in cell therapy solutions for diabetes care. The company's operations have remained consistent, focusing on advancing its proprietary technologies and therapies. The CEO, Paul Laikind, has a history in the biotech field. In July 2022, the company was acquired by Vertex Pharmaceuticals Incorporated for USD 320 mn, enhancing Vertex's stem cell-based programs.ViaCyte, Inc. is committed to delivering advanced cell therapy solutions designed to improve diabetes treatment outcomes. Its primary focus includes developing stem cell-derived islet cell replacement therapies aimed at restoring normal insulin production. The company collaborates with healthcare providers and researchers to provide groundbreaking therapeutic options for diabetic patients, addressing the complexities associated with the disease.The company operates on a subscription-based revenue model, enabling healthcare providers and research institutions to access its cutting-edge therapies through structured partnerships. ViaCyte's transactional framework involves tiered pricing based on treatment plans and patient needs, fostering sustainable relationships and encouraging consistent revenue flow.Looking ahead, ViaCyte plans to leverage its recent acquisition by Vertex Pharmaceuticals to accelerate the development of new therapies for diabetes, including expanded capabilities in stem cell technology. The company will explore opportunities for launching additional products aimed at enhancing patient outcomes, with specific emphasis on the global diabetes market.
Who invested in ViaCyte
17 investors across 7 rounds
See all investors in ViaCyte
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series D
Jun 9, 2021
Amount
$54M
Investors
Series D
Nov 29, 2018
Amount
$36M
Investors
Series C
Jul 8, 2013
Amount
$12M
Investors
Series C
Mar 15, 2007
Amount
$20M
Investors
Series C
Dec 18, 2001
Amount
$5M
Investors
Series B
Oct 3, 2001
Amount
$7M
Investors
Series B
May 16, 2000
Amount
Undisclosed
Investors
Questions about ViaCyte
Who invested in ViaCyte?
ViaCyte has 17 investors on record across 7 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ViaCyte raised?
ViaCyte has raised 7 venture rounds. Sign up free to see how much each round raised and the total.
When did ViaCyte last raise money?
ViaCyte's most recent round on record is a Series D, in Jun 2021.
What does ViaCyte do?
ViaCyte is a biotechnology company.
Where is ViaCyte headquartered?
ViaCyte is headquartered in San Diego, US.
Which VCs invest in companies like ViaCyte?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ViaCyte's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like ViaCyte? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.